Edema Control by Cediranib, a Vascular Endothelial Growth Factor Receptor–Targeted Kinase Inhibitor, Prolongs Survival Despite Persistent Brain Tumor Growth in Mice

PURPOSE: Recent clinical trials of antivascular endothelial growth factor (VEGF) agents for glioblastoma showed promising progression-free and overall survival rates. However, available clinical imaging does not separate antitumor effects from antipermeability effects of these agents. Thus although...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Kamoun, Walid S., Ley, Carsten D., Farrar, Christian T., Duyverman, Annique M., Lahdenranta, Johanna, Lacorre, Delphine A., Batchelor, Tracy T., di Tomaso, Emmanuelle, Duda, Dan G., Munn, Lance L., Fukumura, Dai, Sorensen, A. Gregory, Jain, Rakesh K.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2009
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2739611/
https://ncbi.nlm.nih.gov/pubmed/19332720
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.19.9356
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados